Home » Topics » BioWorld Science

BioWorld Science
RSS

NDFIP1 may be a novel target for prevention and treatment of Parkinson's disease

July 12, 2019

Tracer quantification and assessment of tumor uptake of [18F]afatinib in NSCLC

July 12, 2019

[89Zr]-Daratumumab as a promising new agent for CD38-targeted imaging of myeloma

July 12, 2019

mR-21 as potential prognostic biomarker and therapeutic target in hypertensive heart disease

July 12, 2019

Patient recruitment ongoing in phase I study of CPI-200

July 12, 2019

Pfizer initiates phase II study of PF-06826647 for the treatment of plaque psoriasis

July 12, 2019

Pact Pharma initiates first-in-human study of NeoTCR-P1 in solid tumors

July 12, 2019

UCB studies rozanolixizumab in phase III for generalized myasthenia gravis

July 12, 2019

Naive B cells have tell-tale signature in lupus

July 12, 2019

SO-C101 begins first-in-human study in advanced/metastatic solid tumors

July 11, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...